应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09688 再鼎医药
未开盘 07-22 16:08:56
14.840
+0.260
+1.78%
最高
14.860
最低
14.480
成交量
102.98万
今开
14.720
昨收
14.580
日振幅
2.61%
总市值
147.82亿
流通市值
147.82亿
总股本
9.96亿
成交额
1,520万
换手率
0.10%
流通股本
9.96亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
再鼎医药上涨5.14%,报19.62美元/股
金融界 · 07-22 23:36
再鼎医药上涨5.14%,报19.62美元/股
再鼎医药07月19日获主力加仓253万元 环比增加1231.58%
自选股智能写手 · 07-19
再鼎医药07月19日获主力加仓253万元 环比增加1231.58%
南向资金7月18日净卖出再鼎医药70.34万股 连续3日减持
自选股智能写手 · 07-19
南向资金7月18日净卖出再鼎医药70.34万股 连续3日减持
再鼎医药(09688)上涨5.04%,报15.0元/股
金融界 · 07-18
再鼎医药(09688)上涨5.04%,报15.0元/股
再鼎医药盘中异动 下午盘股价大涨5.05%
自选股智能写手 · 07-18
再鼎医药盘中异动 下午盘股价大涨5.05%
再鼎医药(09688)股价上升5.042%,现价港币$15.0
阿斯达克财经 · 07-18
再鼎医药(09688)股价上升5.042%,现价港币$15.0
再鼎医药现涨超3% 此前获浦银国际维持买入评级
新浪港股 · 07-18
再鼎医药现涨超3% 此前获浦银国际维持买入评级
港股异动 | 再鼎医药(09688)再涨超3% 近日与argenx宣布艾加莫德皮下注射国内获批
智通财经 · 07-18
港股异动 | 再鼎医药(09688)再涨超3% 近日与argenx宣布艾加莫德皮下注射国内获批
再鼎医药(09688.HK)“卫力迦”获国家药监局批准用于治疗全身型重症肌无力患者
阿斯达克财经 · 07-16
再鼎医药(09688.HK)“卫力迦”获国家药监局批准用于治疗全身型重症肌无力患者
港股异动 | 再鼎医药(09688)午后涨超4% 艾加莫德皮下注射国内获批 用于治疗全身型重症肌无力
智通财经 · 07-16
港股异动 | 再鼎医药(09688)午后涨超4% 艾加莫德皮下注射国内获批 用于治疗全身型重症肌无力
再鼎医药和argenx宣布卫力迦®(艾加莫德皮下注射)国内获批用于治疗全身型重症肌无力
美通社 · 07-16
再鼎医药和argenx宣布卫力迦®(艾加莫德皮下注射)国内获批用于治疗全身型重症肌无力
再鼎医药07月12日获主力加仓417万元 环比增加644.64%
自选股智能写手 · 07-12
再鼎医药07月12日获主力加仓417万元 环比增加644.64%
港股异动 | 医药股再度走高 行业投融资有望触底回暖 创新药政策释放积极信号
智通财经 · 07-12
港股异动 | 医药股再度走高 行业投融资有望触底回暖 创新药政策释放积极信号
再鼎医药上涨5.1%,报17.92美元/股
金融界 · 07-12
再鼎医药上涨5.1%,报17.92美元/股
*美银证券降再鼎医药(09688.HK)目标价至16.28元 评级“买入”(更正)
阿斯达克财经 · 07-11
*美银证券降再鼎医药(09688.HK)目标价至16.28元 评级“买入”(更正)
《大行》美银证券降再鼎医药(09688.HK)目标价至16.28元 评级“买入”
阿斯达克财经 · 07-11
《大行》美银证券降再鼎医药(09688.HK)目标价至16.28元 评级“买入”
再鼎医药07月10日主力资金流入18万元 连续7日加仓
自选股智能写手 · 07-10
再鼎医药07月10日主力资金流入18万元 连续7日加仓
再鼎医药07月08日主力资金流入68万元 连续5日加仓
自选股智能写手 · 07-08
再鼎医药07月08日主力资金流入68万元 连续5日加仓
再鼎医药上涨2.32%,报17.62美元/股
金融界 · 07-05
再鼎医药上涨2.32%,报17.62美元/股
再鼎医药07月04日主力资金流入78万元 连续3日加仓
自选股智能写手 · 07-04
再鼎医药07月04日主力资金流入78万元 连续3日加仓
公司概况
公司名称:
再鼎医药
所属市场:
SEHK
上市日期:
--
主营业务:
Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。
发行价格:
--
{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":14.84,"timestamp":1721635736037,"preClose":14.58,"halted":0,"volume":1029800,"delay":0,"floatShares":996087670,"shares":996087670,"eps":-2.703372,"marketStatus":"未开盘","marketStatusCode":0,"change":0.26,"latestTime":"07-22 16:08:56","open":14.72,"high":14.86,"low":14.48,"amount":15202755,"amplitude":0.026063,"askPrice":14.84,"askSize":2500,"bidPrice":14.82,"bidSize":4200,"shortable":3,"etf":0,"ttmEps":-2.730065660548238,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"listingDate":1601222400000,"adjPreClose":14.58,"openAndCloseTimeList":[[1721611800000,1721620800000],[1721624400000,1721635200000]],"volumeRatio":0.301629,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688/wiki","defaultTab":"wiki","newsList":[{"id":"2453205792","title":"再鼎医药上涨5.14%,报19.62美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453205792","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453205792?lang=zh_cn&edition=full","pubTime":"2024-07-22 23:36","pubTimestamp":1721662613,"startTime":"0","endTime":"0","summary":"7月22日,再鼎医药(ZLAB)盘中上涨5.14%,截至23:36,报19.62美元/股,成交235.74万美元。财务数据显示,截至2024年03月31日,再鼎医药收入总额8714.9万美元,同比增长38.78%;归母净利润-5347.1万美元,同比减少8.8%。大事提醒:8月6日,再鼎医药将于(美东)盘后披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/22233641723379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1588","09688","BK4139","BK1574","ZLAB","BK4585","BK4548","BK4588","BK1161","BK4531","BK4526"],"gpt_icon":0},{"id":"2452494244","title":"再鼎医药07月19日获主力加仓253万元 环比增加1231.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452494244","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452494244?lang=zh_cn&edition=full","pubTime":"2024-07-19 16:16","pubTimestamp":1721376990,"startTime":"0","endTime":"0","summary":"07月19日, 再鼎医药股价跌3.44%,报收14.58元,成交金额5921万元,换手率0.40%,振幅3.58%,量比1.24。再鼎医药今日主力资金净流入253万元,连续3日净流入,上一交易日主力净流入19万元,今日环比增加1231.58%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为57.14%,平均涨幅为4.38%。该股近5个交易日上涨2.00%,主力资金累计净流入541万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入942万元,其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071916172595db866f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071916172595db866f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1574","BK1161","BK1588"],"gpt_icon":0},{"id":"2452493778","title":"南向资金7月18日净卖出再鼎医药70.34万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2452493778","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452493778?lang=zh_cn&edition=full","pubTime":"2024-07-19 09:31","pubTimestamp":1721352700,"startTime":"0","endTime":"0","summary":"7月18日,南向资金减持再鼎医药70.34万股连续3日减持。截止当日收盘,港股通共持有再鼎医药9915.45万股,占流通股9.94%。港股通减持金额前五个股分别为香港交易所、中国神华、中国宏桥、理想汽车-W、东岳集团。再鼎医药近5个交易日上涨12.69%,港股通累计减持147.24万股;近20个交易日上涨5.30%,港股通累计减持191.61万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071909435595d9acbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071909435595d9acbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","09688","BK1574","BK1161","ZLAB"],"gpt_icon":0},{"id":"2452127200","title":"再鼎医药(09688)上涨5.04%,报15.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452127200","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452127200?lang=zh_cn&edition=full","pubTime":"2024-07-18 14:35","pubTimestamp":1721284548,"startTime":"0","endTime":"0","summary":"7月18日,再鼎医药(09688)盘中上涨5.04%,截至14:35,报15.0元/股,成交4127.84万元。再鼎医药有限公司主要业务是研发和销售针对肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病的创新药物,以满足全球患者的医疗需求。关键经营数据方面,公司以其强大的研发能力和全球化运营策略,致力于成为全球领先的生物制药公司。截至2024年一季报,再鼎医药营业总收入6.18亿元、净利润-3.79亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/18143541642834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK4139","BK1161","BK4526","BK1588","09688","BK4531","ZLAB","BK4588","BK4585","BK4548"],"gpt_icon":0},{"id":"2452875120","title":"再鼎医药盘中异动 下午盘股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452875120","media":"自选股智能写手","labels":["movement"],"top":-1,"share":"https://www.laohu8.com/m/news/2452875120?lang=zh_cn&edition=full","pubTime":"2024-07-18 14:35","pubTimestamp":1721284545,"startTime":"0","endTime":"0","summary":"2024年07月18日下午盘14时35分,再鼎医药股票出现波动,股价急速上涨5.05%。截至发稿,该股报15.001港元/股,成交量278.43万股,换手率0.28%,振幅3.78%。资金方面,该股资金流入2104.25万港元,流出1651.07万港元。再鼎医药股票所在的生物技术行业中,整体涨幅为0.03%。其相关个股中,北海康成-B、盛禾生物-B、维亚生物涨幅较大,振幅较大的相关个股有北海康成-B、盛禾生物-B、宜明昂科-B,振幅分别为28.57%、15.23%、12.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407181435459681e04c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407181435459681e04c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1161","BK1574","09688"],"gpt_icon":0},{"id":"2452212011","title":"再鼎医药(09688)股价上升5.042%,现价港币$15.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2452212011","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452212011?lang=zh_cn&edition=full","pubTime":"2024-07-18 14:35","pubTimestamp":1721284500,"startTime":"0","endTime":"0","summary":"[上升股]再鼎医药(09688) 股价在下午02:35比前收市价上升5.042%,现股价为港币$15.0。至目前为止,今日最高价为$15.0,而最低价为$14.46。总成交量为275.03万股,总成交金额为港币$4.065千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407181104/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09688","BK1588","BK1161","BK1574"],"gpt_icon":0},{"id":"2452146516","title":"再鼎医药现涨超3% 此前获浦银国际维持买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2452146516","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452146516?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:54","pubTimestamp":1721267684,"startTime":"0","endTime":"0","summary":"再鼎医药(09688)早盘上涨3.08%,现报14.72港元,成交额1173.18万港元。\n 近日,再鼎医药和argenx宣布,艾加莫德皮下注射制剂获国家药监局批准上市,与常规治疗药物联合,用于治疗乙酰胆碱受体抗体阳性的成人全身型重症肌无力(gMG)患者。这也是国内首个获批治疗全身型重症肌无力的皮下注射制剂。\n 浦银国际此前研报认为,维持再鼎医药“买入”评级,将2024E、2025E收入分别上调7.5%、3.1%,主要由于上调艾加莫德和即将获批新药物收入导致。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-18/doc-incephkf2205438.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-18/doc-incephkf2205438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["09688"],"gpt_icon":0},{"id":"2452454491","title":"港股异动 | 再鼎医药(09688)再涨超3% 近日与argenx宣布艾加莫德皮下注射国内获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2452454491","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452454491?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:44","pubTimestamp":1721267063,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,再鼎医药(09688)再涨超3%,截至发稿,涨3.50%,报14.78港元,成交额931.22万港元。消息面上,近日,再鼎医药和argenx宣布,艾加莫德皮下注射制剂获国家药监局批准上市,与常规治疗药物联合,用于治疗乙酰胆碱受体抗体阳性的成人全身型重症肌无力(gMG)患者。这也是国内首个获批治疗全身型重症肌无力的皮下注射制剂。浦银国际此前研报认为,维持再鼎医药“买入”评级,将2024E、2025E收入分别上调7.5%、3.1%,主要由于上调艾加莫德和即将获批新药物收入导致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSCEI","YANG","BK4526","ZLAB","BK4139","BK1588","09688","BK1161","BK1574","BK4548","BK4585","HSTECH","BK4531","BK4588"],"gpt_icon":1},{"id":"2451953201","title":"再鼎医药(09688.HK)“卫力迦”获国家药监局批准用于治疗全身型重症肌无力患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2451953201","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451953201?lang=zh_cn&edition=full","pubTime":"2024-07-16 14:33","pubTimestamp":1721111580,"startTime":"0","endTime":"0","summary":"再鼎医药公布,与argenx合作的艾加莫德皮下注射“卫力迦”,其生物制品上市许可申请已获得国家药监局批准,与常规治疗药物联合,用于治疗乙酰胆堿受体抗体阳性的成人全身型重症肌无力患者。再鼎医药总裁兼全球研发负责人Rafael G. Amado表示,非常高兴国家药监局批准卫力迦的上市申请,将可为中国gMG患者提供另一种FIC的治疗选择,除提升疗程的灵活性外,亦有望进一步简化治疗方案,让治疗的可及性提高。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230802095624300_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230802095624300_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1363972/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1588","09688","BK1161","BK1574"],"gpt_icon":0},{"id":"2451937583","title":"港股异动 | 再鼎医药(09688)午后涨超4% 艾加莫德皮下注射国内获批 用于治疗全身型重症肌无力","url":"https://stock-news.laohu8.com/highlight/detail?id=2451937583","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451937583?lang=zh_cn&edition=full","pubTime":"2024-07-16 13:35","pubTimestamp":1721108137,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,再鼎医药(09688)午后涨超4%,截至发稿,涨3.64%,报14.24港元,成交额2988.5万港元。消息面上,再鼎医药午间宣布,国家药品监督管理局已经批准了卫力迦®(艾加莫德皮下注射,1000mg(5.6ml)/瓶)的生物制品上市许可申请,与常规治疗药物联合,用于治疗乙酰胆碱受体(AChR)抗体阳性的成人全身型重症肌无力(gMG)患者。浦银国际此前指出,艾加莫德增长势头愈发强劲,维持全年七千万美元销售指引。该行表示,随着持续放量及适应症拓展,艾加莫德有望为再鼎医药实现其战略目标(2023-2028年均复合收入增长率超过50%)提供强有力的驱动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","09688","BK4139","BK1161","BK4548","BK4588","BK4526","BK4585","HSTECH","BK4531","HSCEI","YANG","BK1574","07226","ZLAB"],"gpt_icon":0},{"id":"2451937790","title":"再鼎医药和argenx宣布卫力迦®(艾加莫德皮下注射)国内获批用于治疗全身型重症肌无力","url":"https://stock-news.laohu8.com/highlight/detail?id=2451937790","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451937790?lang=zh_cn&edition=full","pubTime":"2024-07-16 13:33","pubTimestamp":1721107980,"startTime":"0","endTime":"0","summary":"在全球3 期临床研究ADAPT-SC 中,艾加莫德皮下注射表现出和艾加莫德静脉输注一致的临床获益和安全性。\" 艾加莫德皮下注射的获批是基于全球3期ADAPT-SC研究的阳性结果。艾加莫德是首个获批的FcRn拮抗剂,用于治疗乙酰胆碱受体抗体阳性的成人全身型重症肌无力患者。关于argenxargenx是一家全球性的免疫学公司,致力于改善严重自身免疫性疾病患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4462332_ZH62332_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4585","BK4531","ZLAB","BK1588","BK1161","BK4139","BK4588","BK4526","BK4548","09688","BK1574"],"gpt_icon":0},{"id":"2450308645","title":"再鼎医药07月12日获主力加仓417万元 环比增加644.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450308645","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450308645?lang=zh_cn&edition=full","pubTime":"2024-07-12 16:16","pubTimestamp":1720772193,"startTime":"0","endTime":"0","summary":"07月12日, 再鼎医药股价涨4.48%,报收14.00元,成交金额4288万元,换手率0.31%,振幅2.99%,量比1.60。再鼎医药今日主力资金净流入417万元,上一交易日主力净流入56万元,今日环比增加644.64%。近一年数据显示,该股主力连续9日净流入后,次日上涨概率为66.67%,平均涨幅为2.99%。该股近5个交易日上涨3.26%,主力资金累计净流入642万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入739万元,其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071216170495abfffa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071216170495abfffa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","BK1161","BK1588","BK1574"],"gpt_icon":0},{"id":"2450347109","title":"港股异动 | 医药股再度走高 行业投融资有望触底回暖 创新药政策释放积极信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2450347109","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450347109?lang=zh_cn&edition=full","pubTime":"2024-07-12 09:56","pubTimestamp":1720749399,"startTime":"0","endTime":"0","summary":"消息面上,美国6月CPI超预期放缓,9月降息概率冲至近90%。太平洋证券指出,未来随着美联储加息周期结束,流动性逐步宽松有望带来投融资回暖,海外需求将先于本土需求改善。此外,《全链条支持创新药发展实施方案》近期出台释放积极信号。东吴证券认为,具体条款有望近期落地,叠加创新药板块处于历史相对底部位置,下半年有ESMO大会、WCLC大会、医保谈判、创新药出海预期等多重催化,创新药板块有望走强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","HK0000320223.HKD","HK0000320264.USD","09939","BK1161","159992","BK1141","BK1576","HSCEI","BK1588","06978","YANG","BK1583","159938","HSTECH","LU0196878994.USD","06990","01548","BK1515","09688","HK0000306685.HKD","HK0000306701.USD","07226","09969"],"gpt_icon":0},{"id":"2450393615","title":"再鼎医药上涨5.1%,报17.92美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450393615","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450393615?lang=zh_cn&edition=full","pubTime":"2024-07-12 00:35","pubTimestamp":1720715732,"startTime":"0","endTime":"0","summary":"7月12日,再鼎医药(ZLAB)盘中上涨5.1%,截至00:35,报17.92美元/股,成交235.35万美元。财务数据显示,截至2024年03月31日,再鼎医药收入总额8714.9万美元,同比增长38.78%;归母净利润-5347.1万美元,同比减少8.8%。大事提醒:8月5日,再鼎医药将披露2024财年中报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/12003541527432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1574","09688","BK4526","BK4531","BK4139","BK4585","BK1161","BK4588","ZLAB","BK4548","BK1588"],"gpt_icon":0},{"id":"2450429801","title":"*美银证券降再鼎医药(09688.HK)目标价至16.28元 评级“买入”(更正)","url":"https://stock-news.laohu8.com/highlight/detail?id=2450429801","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450429801?lang=zh_cn&edition=full","pubTime":"2024-07-11 12:22","pubTimestamp":1720671720,"startTime":"0","endTime":"0","summary":"(更正:2024-07-11 11:53:51 *美银证券降再鼎医药(09688.HK) 目标价至16.28元 评级“买入”)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-10 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230802095624816_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230802095624816_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1362924/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09688","161027"],"gpt_icon":0},{"id":"2450801251","title":"《大行》美银证券降再鼎医药(09688.HK)目标价至16.28元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2450801251","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450801251?lang=zh_cn&edition=full","pubTime":"2024-07-11 12:09","pubTimestamp":1720670940,"startTime":"0","endTime":"0","summary":"美银证券发表研究报告指,再鼎医药(09688.HK) 一种PARP抑制剂的NDA审查已于今年6月由药品审查中心(CDE)完成,最快可能在今年获得批准,这将加剧市场竞争。该行表示,鉴于再鼎医药最新的销售业绩以及PARPi市场潜在的日益激烈的竞争,该行将集团2024至26的收入预期分别小幅下调0.2%、0.4%及1.9%,又将港股目标价由从19.38元降至16.28元,美股目标价由25美元降至21美元,重申“买入”评级,以反映集团的强大的研发和商业化能力。(sl/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-10 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220425152914431_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220425152914431_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1362927/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09688","161027"],"gpt_icon":0},{"id":"2450274857","title":"再鼎医药07月10日主力资金流入18万元 连续7日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2450274857","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450274857?lang=zh_cn&edition=full","pubTime":"2024-07-10 16:16","pubTimestamp":1720599371,"startTime":"0","endTime":"0","summary":"07月10日, 再鼎医药股价涨0.78%,报收12.96元,成交金额2284万元,换手率0.18%,振幅2.80%,量比1.07。再鼎医药今日主力资金净流入18万元,连续7日净流入,上一交易日主力净流入81万元,今日环比减少77.78%。近一年数据显示,该股主力连续7日净流入后,次日上涨概率为44.44%,平均涨幅为3.79%。该股近5个交易日下跌3.86%,主力资金累计净流入383万元;近20日主力资金累计净流入437万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710161634959d3d4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710161634959d3d4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1574","BK1161","09688"],"gpt_icon":0},{"id":"2449723760","title":"再鼎医药07月08日主力资金流入68万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2449723760","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449723760?lang=zh_cn&edition=full","pubTime":"2024-07-08 16:15","pubTimestamp":1720426518,"startTime":"0","endTime":"0","summary":"07月08日, 再鼎医药股价跌2.23%,报收13.18元,成交金额1968万元,换手率0.15%,振幅3.12%,量比0.80。再鼎医药今日主力资金净流入68万元,连续5日净流入,上一交易日主力净流入137万元,今日环比减少50.36%。近一年数据显示,该股主力连续5日净流入后,次日上涨概率为41.67%,平均涨幅为3.80%。该股近5个交易日下跌1.64%,主力资金累计净流入683万元;近20日主力资金累计净流入945万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081615319f1d5e68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081615319f1d5e68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","09688","BK1161","BK1574"],"gpt_icon":0},{"id":"2449260195","title":"再鼎医药上涨2.32%,报17.62美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449260195","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449260195?lang=zh_cn&edition=full","pubTime":"2024-07-05 21:32","pubTimestamp":1720186364,"startTime":"0","endTime":"0","summary":"7月5日,再鼎医药(ZLAB)开盘上涨2.32%,截至21:32,报17.62美元/股,成交7.64万美元。财务数据显示,截至2024年03月31日,再鼎医药收入总额8714.9万美元,同比增长38.78%;归母净利润-5347.1万美元,同比减少8.8%。大事提醒:8月5日,再鼎医药将披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/05213241410307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4139","BK1574","BK4588","09688","BK1161","BK4585","BK1588","BK4531","BK4548","ZLAB","BK4526"],"gpt_icon":0},{"id":"2448955414","title":"再鼎医药07月04日主力资金流入78万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2448955414","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448955414?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:16","pubTimestamp":1720080982,"startTime":"0","endTime":"0","summary":"07月04日, 再鼎医药股价跌1.93%,报收13.22元,成交金额1325万元,换手率0.10%,振幅4.60%,量比0.36。再鼎医药今日主力资金净流入78万元,连续3日净流入,上一交易日主力净流入279万元,今日环比减少72.04%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为57.14%,平均涨幅为4.59%。该股近5个交易日下跌7.26%,主力资金累计净流入145万元;近20日主力资金累计净流入1093万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041616519573d550&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041616519573d550&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1161","BK1574","09688"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0801},{"period":"1month","weight":0.0801},{"period":"3month","weight":0.2285},{"period":"6month","weight":-0.1719},{"period":"1year","weight":-0.3645},{"period":"ytd","weight":-0.3098}],"compareEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.048},{"period":"6month","weight":0.1092},{"period":"1year","weight":-0.0755},{"period":"ytd","weight":0.0345}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.016509},{"month":2,"riseRate":0.5,"avgChangeRate":-0.001648},{"month":3,"riseRate":0,"avgChangeRate":-0.143693},{"month":4,"riseRate":0.75,"avgChangeRate":0.076104},{"month":5,"riseRate":0.5,"avgChangeRate":-0.025575},{"month":6,"riseRate":0.25,"avgChangeRate":-0.052584},{"month":7,"riseRate":0.75,"avgChangeRate":0.063766},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.00144},{"month":9,"riseRate":0,"avgChangeRate":-0.186765},{"month":10,"riseRate":0.5,"avgChangeRate":-0.079493},{"month":11,"riseRate":0.75,"avgChangeRate":0.139277},{"month":12,"riseRate":0.5,"avgChangeRate":0.014831}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}